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Abstract: Accumulating evidence suggests that 7 nicotinic receptors (7 nAChRs), a subtype of nAChRs, play a role in 
the pathophysiology of neuropsychiatric diseases, including schizophrenia and Alzheimer’s disease (AD). A number of 
psychopharmacological and genetic studies shown that 7 nAChRs play an important role in the deficits of P50 auditory 
evoked potential in patients with schizophrenia, and that 7 nAChR agonists would be potential therapeutic drugs for 
cognitive impairments associated with P50 deficits in schizophrenia. Furthermore, some studies have demonstrated that 
7 nAChRs might play a key role in the amyloid- (A)-mediated pathology of AD, and that 7 nAChR agonists would 
be potential therapeutic drugs for A deposition in the brains of patients with AD. Interestingly, the altered expression of 
7 nAChRs in the postmortem brain tissues from patients with schizophrenia and AD has been reported. Based on all 
these findings, selective 7 nAChR agonists can be considered potential therapeutic drugs for cognitive impairments in 
both schizophrenia and AD. In this article, we review the recent research into the role of 7 nAChRs in the 
pathophysiology of these diseases and into the potential use of novel 7 nAChR agonists as therapeutic drugs. 
Keywords: 7 Nicotinic receptors, Cognition, Schizophrenia, Alzheimer’s disease. 
7 NICOTINIC ACETYLCHOLINE RECEPTORS 
 ( S)-(-)-Nicotine (Fig. 1, hereafter simply nicotine), the 
main addictive component of tobacco, activates and 
desensitizes nicotinic acetylcholine receptors (nAChRs). In 
the central nervous system (CNS), nAChRs normally 
respond to acetylcholine (ACh) (Fig. 1) and modulate 
neuronal excitability and synaptic communication [1-4]. The 
health consequences of smoking and the mechanisms 
involved in nicotine dependence continue to be subjects of 
great interest [5-9]. In addition, recent attention has been 
directed to the potential role of nAChRs in diseases and 
therapeutic targets [10-23].  
  The nAChRs are ligand-gated ion channels that are 
distributed throughout the human CNS and that each consists 
of five subunits (a combination of  and  subunits). At 
present, nine  (2-10) and three  (2-4) subunits have 
been identified and cloned in humans. The numerous 
combinations of  and  subunits or of  subunits alone can 
generate many subtypes of nAChRs with different 
physiologies, pharmacologies and anatomical distributions 
[4]. Two major subtypes exist in the brain, those comprised 
of  42 and those comprised of 7 subunits. The former 
contribute >90% of the high affinity binding sites for 
nicotine in the rat brain [24]. The low affinity binding sites 
(7 subunits) for nicotine are recognized by their nanomolar  
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affinity for -bungarotoxin [25]. The 7 nAChRs have an 
unusually high permeability to Ca
2+ compared to other 
subtypes and exhibit exceptionally rapid desensitization 
following exposure to agonists [8, 26-30]. Choline (Fig. 1) is 
an essential physiological component of the cerebrospinal 
fluid (CSF) and is important for the structural integrity of 
cell membranes, ACh synthesis, and lipid and cholesterol 
transport and metabolism. Several lines of evidence suggest 
that choline is a full agonist of 7 nAChRs, but not other 
nAChR subtypes [31-34].  
 The  7 nAChRs are assumed to comprise five 7 
subunits and to differ from other subtypes of nAChRs. In 
particular, the 7 nAChRs may play a distinct role in 
regulating neuronal plasticity. By elevating intracellular Ca
2+ 
levels in discrete neuronal locations, these ligand-gated ion 
channels may influence numerous physiological processes in 
the developing and adult CNS [4, 23, 26, 27, 35]. Several 
lines of evidence suggest that both pre- and postsynaptic 7 
nAChRs modulate neurotransmitter release in the brain 
through Ca
2+-dependent mechanisms, and that the 7 
nAChRs play a role in regulating neuronal growth and 
differentiation in the developing CNS [4, 26, 35-38]. 
Furthermore, it has been proposed that intracellular Ca
2+ may 
be coregulated by N-methyl-D-aspartate (NMDA) receptors 
and  7 nAChRs in the brain [26]. Together with NMDA 
receptors, postsynaptic 7 nAChRs may serve to regulate 
intracellular Ca
2+ levels in neurons, whereas presynaptic 7 
nAChRs could serve as a feedback mechanism for 
modulating glutamatergic transmission. Thus, it is possible 
that a close interaction between cholinergic and 
glutamatergic pathways, mediated by 7 nAChRs and 
NMDA receptors, may play a role in the pathophysiology of 38    The Open Medicinal Chemistry Journal, 2010, Volume 4  Toyohara and Hashimoto 
neuropsychiatric diseases such as schizophrenia and 
Alzheimer’s disease (AD) [4, 23, 26, 35-41]. 
  In this article, we review the role of 7 nAChRs in the 
pathophysiology of neuropsychiatric diseases such as 
schizophrenia and AD. In addition, we also review recent 
advances in the potential use of 7 nAChR agonists as 
therapeutic drugs for these diseases. 
SCHIZOPHRENIA AND 7 nAChRs 
  The binding sites (7 subtype) labeled by [
125I]-
bungarotoxin are different from the high affinity binding 
sites (42 subtype) for nicotine [42]. In the hippocampus, 
[
125I]-bungarotoxin binds most intensely to inhibitory 
interneurons in the CA3 region of Ammon’s horn and in the 
hilus of the dentate gyrus [43]. The authors of the latter study 
subsequently suggested that inhibitory interneurons with 7 
nAChRs are possible candidates for medication of the 
habituation of auditory responses in the hippocampus 
because activation of the interneurons via 7 nAChRs would 
increase the inhibitory synaptic input to pyramidal neurons 
and thereby diminish the responsiveness of these pyramidal 
neurons to sensory stimulation [44]. This parallels studies of 
postmortem human tissue that documented a decreased 
expression of hippocampal 7 nAChRs in schizophrenic 
patients [45]. It has been shown that [
125I]-bungarotoxin 
binding is reduced in the thalamic reticular nucleus of 
schizophrenic subjects [46], and that 7 nAChR protein 
levels are reduced in the frontal cortex in patients with 
schizophrenia [47]. Furthermore, Marutle et al. [48] 
observed a reduction of 7 nAChRs but an increase of 
[
3H]cytisine binding to 42 nAChRs in the cingulate cortex 
of schizophrenic patients. Thus, it seems that schizophrenic 
patients have fewer 7 nAChRs in the hippocampus, a 
condition which may lead to failure of cholinergic activation 
of inhibitory interneurons, clinically manifested as decreased 
gating of the response to sensory stimulation [23, 37, 44, 49, 
50]. 
  In regard to the search for peripheral biological markers 
for schizophrenia, Perl et al. [51] investigated the mRNA 
levels of 7 nAChRs in peripheral blood lymphocytes of 
schizophrenic patients and healthy controls. They found a 
significant reduction of 7 nAChR mRNA levels on 
lymphocytes of schizophrenic patients [51]. This reduction 
was not a result of medication, because the non-medicated 
patients displayed the same levels of reduction in 7 nAChR 
mRNA. In addition, the possibility that the observed 
decrease in 7 nAChR mRNA levels resulted from nicotine 
consumption in smoking was excluded, because healthy 
smokers exhibited the same levels of 7 nAChR mRNA as 
non-smokers [51]. These findings suggest that mRNA levels 
of 7 nAChRs in peripheral blood lymphocytes may serve as 
a reliable peripheral biological marker for schizophrenia.  
SENSORY GATING DEFICITS IN SCHIZOPHRENIA 
AND 7 nAChRs 
  Our knowledge of the deficits of sensory gating in 
schizophrenia derives from the clinical observation that 
patients report failures of information processing 
characterized by poor sensory gating [44, 52-54]. The 
underlying problem is evident in the inability of people with 
schizophrenia to adequately filter their response to incoming 
sensory stimulation, as measured by their inhibitory 
processing of the P50 auditory evoked potential. The P50 
auditory evoked potential is a positive electroencephalogra-
phic waveform that occurs 50 msec after presentation of an 
auditory stimulus. When pairs of auditory stimuli are 
presented, with a 500 msec interstimulus interval, schizo-
phrenic patients fail to adequately inhibit the P50 response to 
the second stimulus. Normal subjects, however, have 
significantly reduced responses to the second stimulus [44, 
52, 54, 55]. The reduced response to the second stimulus 
reflects inhibitory processing of the information that may 
function to protect the individual from being overwhelmed 
by incoming, repetitive sensory information. It is known that 
nicotine transiently normalizes the deficits in P50 auditory 
evoked potential in schizophrenic patients [56, 57].  
  Genetic linkage analysis of deficits in P50 auditory 
evoked potential in families of patients with schizophrenia 
has revealed a peak LOD score at 15q13-q14, and the LOD 
score was 5.3 (theta=0.00) at the D15S1360 marker, which is 
located in intron 2 of the gene for the 7 nAChR subunit 
(CHRNA7) [58]. The CHRNA7 gene is located on 
chromosome 15q13-q14, a region linked with schizophrenia 
in several earlier studies [59, 60]. The CHRNA7 has a partial 
duplication of exons 5-10, including the intervening introns 
(CHRFAM7) that map approximately 0.5 Mb proximal to 
the full-length CHRNA7 gene [61]. The D15S1360 
microsatellite repeats, in intron 2 of the CHRNA7 gene, 
cosegregate with an auditory gating deficit in family linkage 
studies of schizophrenic patients [58]. Furthermore, in a 
mutation screening of the CHRNA7 gene from 
schizophrenics and controls, Leonard et al. [62] identified 
the promoter polymorphisms that decreased the subunit 
transcription and P50 inhibition in schizophrenia. Moreover, 
an association has been demonstrated between the 
homozygous 113 bp allele on the D15S1360 polymorphism 
of the CNRNA7 gene and smoking risk in schizophrenia 
[63]. Taken together, these results suggest that the CHRNA7 
gene is likely susceptible to the deficits of P50 sensory 
gating in schizophrenia [10, 23, 44, 49, 50, 53, 58, 63-67]. 
Interestingly, a 2 bp deletion in exon 6 of CHRFAM7A, 
which disrupts the hybrid gene for the CHRNA7 gene, was 
associated with episodic memory performance in 
schizophrenia, suggesting that the CHRFAM7A/CHRNA7 
 
 
 
 
Fig. (1). Chemical structures of (S)-(-)-nicotine, acetylcholine (ACh) and choline. 
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locus plays a role in modulating episodic memory function 
[68]. 
  Taken together, these results suggest that 7 nAChRs 
likely play an important role in the deficits of P50 auditory 
evoked potential in patients with schizophrenia, and that 7 
nAChR agonists would be potential therapeutic drugs for 
cognitive impairments associated with P50 deficits in 
schizophrenia [10, 23, 64, 65, 69, 70]. 
ALZHEIMER’S DISEASE (AD) AND 7 nAChRs 
  Identification of the loss of cholinergic neurons in the 
basal forebrain and of cholinergic innervations of the 
cerebral cortex in Alzheimer’s disease (AD) [71-73] was 
followed by investigations into the involvement of 
cholinergic receptors. With regard to 7 nAChR protein 
expression, the investigations show conflicting results. For 
example, it has been reported that there is no significant 
relation between [
125I]-bungarotoxin binding in the frontal 
cortex and AD [74, 75]. Although an early study of Davies 
and Feisullin [74] reported a 40% reduction in [
125I]-
bungarotoxin binding in the temporal cortex of patients with 
AD, this was not replicated [76]. The results of most studies 
show no significant [77, 78] or minor [79] loss of 7 subunit 
protein levels in the temporal cortex of patients with AD, 
although a reduction has been demonstrated in the frontal 
cortex of such patients [80]. In the hippocampus, a 25% 
reduction in [
125I]-bungarotoxin binding (as revealed using 
membrane homogenate) was observed in patients with AD 
relative to age-matched control subjects, although the 
number of control cases studied was small [76]. However, an 
autoradiographic investigation did not detect significant 
changes in [
125I]-bungarotoxin binding in a large series of 
patients with AD, but rather, in common with Burghaus et 
al. [79], a considerable variation in the density of the 7 
receptor subtype was seen among patients with AD [81]. 
Such variation in 7 nAChR expression may reflect disease 
severity, and it should be evaluated in cohorts of patients 
with detailed clinical and pathological assessments. Despite 
a reported 36% reduction in 7 protein expression in the 
hippocampal formation of patients with AD [77], a 65% 
increase in 7 subunit mRNA expression has also been 
demonstrated in patients with AD [76], suggesting the 
possibility of a compensatory mechanism. Recently, Counts 
et al. [82] reported that 7 nAChR was up-regulated in 
cholinergic basal forebrain neurons in patients with AD. In 
the same study, dysfunction of the basocortical cholinergic 
projection neurons of the nucleus basalis (NB) was 
correlated with cognitive deficits in AD. The authors found 
that cholinergic NB neurons displayed a statistically 
significant up-regulation of 7 nAChR mRNA expression in 
subjects with mild to moderate AD compared with those 
with no cognitive impairment (NCI) or mild cognitive 
impairment (MCI) (P<0.001). The expression levels of 7 
nAChRs were inversely associated with the Global 
Cognitive Score and with Mini-Mental State Examination 
performance. Very recently, Ikonomovic et al. [83] found 
that increased 7 nAChR binding of [
3H]methyllycaconitine 
(MLA)( Fig. 2) was associated with diagnosis of AD based 
on the National Institute on Aging-Reagan Institute criteria 
(P=0.02) and, albeit weakly, the presence of cortical -
amyloid (A) plaque in AD (P=0.08). Taken together, these 
results suggest that the up-regulation of 7 nAChR may 
occur as a compensatory mechanism to maintain neuronal 
function during AD progression [83]. Furthermore, it has 
been reported that genetic variation (rs6494223) in the 
CHRNA7 gene is associated with delusional symptoms in 
AD [84], suggesting that 7 nAChRs may be a suitable 
target for the treatment of AD with psychosis. In addition, 
patients with Alzheimer's disease have also been reported to 
show deficits of P50 auditory sensory gating relative to 
controls [85]. It has also been suggested that the disturbed 
sensory gating in patients with AD might result from 
cholinergic dysfunction or 7 nAChR loss. 
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Fig. (2). Chemical structure of MLA. 
 
-AMYLOID AND 7 nAChRs 
  -Amyloid (A) binds with high affinity to neuronal 7 
nAChRs [86, 87]. This interaction leads to intraneuronal 
accumulation of A1-42 (A42) 7 nAChR complexes [88], 
rapid tau phosphorylation [89], severe impairment of 7 
nAChR channels [90, 91], cholinergic neurotransmission 
defects [92], and neuronal cell death [86]. These findings 
indicate that chronic perturbation of the 7 nAChRs by A42 
in AD brains could cause neuronal dysfunction and 
neurodegeneration, resulting in the accumulation of A-rich 
amyloid plaques and phosphorylated tau-containing 
neurofibrillary tangles (NFTs). Recently, Dziewczapolski et 
al. [93] showed that, despite the presence of high amounts of 
amyloid precursor protein (APP) and amyloid deposits, 
deleting the 7 nAChR subunit in the mouse model of AD 
leads to protection from dysfunction in synaptic integrity 
(pathology and plasticity) and learning and memory 
behavior. Hence, disrupting the A427 nAChR interaction 
may represent a novel approach to reducing A42-mediated 
functional deficits, neurodegeneration, and possibly the 
clinicopathological features of AD. 
  Taken together, these results suggest that 7 nAChRs are 
likely to play a key role in the A-mediated pathology of 
AD, and that 7 nAChR agonists would be potential 
therapeutic drugs for AD [39, 40, 93, 94]. 
7 NICOTINIC RECEPTOR AGONISTS 
3-(2,4)-Dimethoxybenzilidine Anabaseine (DMXB-A; 
Also Known as GTS-21) 
  While there are a number of nicotinic receptor agonists 
known to be selective for the 42 subtype, there are some 40    The Open Medicinal Chemistry Journal, 2010, Volume 4  Toyohara and Hashimoto 
agonists which bind the 7 nAChRs selectively over other 
subtypes [13, 18, 20]. Anabaseine (2-(3-pyridyl)-3,4,5,6-
tetrahydropyridine) (Fig. 3), a naturally occurring substance 
in nemertines, is an agonist at the neuromuscular junction 
[95] and is structurally related to nicotine. The better known 
compound anabasine (neonicotine; 3-(2-piperidinyl)pyrid-
ine) (Fig. 3) is a weak nicotinic alkaloid found in tobacco 
that lacks the imine double bond present in anabaseine. 
Three analogues of anabaseine, 3-(2,4)-dimethoxybenzi-
lidine anabaseine (DMXB-A; also known as GTS-21), 3-(4)-
dimethylaminobenzylidine anabaseine (DMAB), and 3-(4)-
dimethylaminocinnamylidine (DMAC), have been reported 
to be functionally selective for the 7 nAChRs [96] (Fig. 3). 
Compared with anabaseine and the other derivatives, DMAC 
was found to be the most potent at displacing [
125I]-
bungarotoxin binding (putative 7 subtype) and the least 
potent at displacing [
3H]cytisine binding (putative 42 
subtype) to brain membranes. These anabaseine derivatives 
were partial agonists at 7 nAChRs [96]. Furthermore, 
DMXB-A bound to human 42 nAChRs (Ki=20 nM) 100-
fold more potently than to human 7 nAChRs, and was 18- 
and 2-fold less potent than ()-nicotine at human 42 and 
7 nAChRs, respectively [97]. The primary human 
metabolite, 3-(4-hydroxy-2-methoxybenzylidine) anabaseine 
(4-OH DMXB-A; Fig. 3), of DMXB-A exhibited a similar 
level of efficacy for human 7 nAChRs [98, 99].  
  Initial (phase I) clinical studies on DMXB-A have been 
reported [100]. DMXB-A was administered to 87 healthy 
volunteers. Initially, the effects of single doses (range, 1-250 
mg) were assessed. The elimination half-life ranged between 
0.5 and 1.0 h for DMXB-A and its major phase I metabolite, 
4-OH DMXB-A. No serious adverse effects were reported at 
these doses. At twice daily doses of 75 and 150 mg for 5 
days, DMXB-A improved the cognitive function of young 
adult volunteers. Furthermore, DMXB-A improved long-
term memory as well as working memory and attention, as 
measured by the Cognitive Drug Research test battery [100]. 
A randomized, placebo-controlled, multiple dose study of 
the safety, pharmacokinetics and cognitive effects of 
DMXB-A in healthy volunteers was also reported [101]. A 
total of 18 subjects were randomized to receive DMXB-A 
(25, 75, and 150 mg) or a placebo administered three times 
daily for 5 days with a 10 day washout period between drug-
taking periods. DMXB-A was well tolerated up to doses of 
450 mg/day, with no clinically significant safety findings. 
Peak plasma levels (Cmax) were achieved at 1-1.4 h after the 
first dose and 1-1.2 h after 5 days of dosing. Cmax and the 
area under the plasma concentration-time curve (AUC) of 
DMXB-A and metabolite 4-OH-DMXB-A increased in a 
dose-related manner. DMXB-A showed statistically 
significant enhancement of three measures of cognitive 
function (attention, working memory, and episodic second 
memory) compared to placebo. A relationship between 
exposure to DMBX-A and the magnitude of the cognitive 
response was apparent, with a maximal effect observed for 
doses between 75 and 150 mg three times a day.  
  Because DMXB-A appeared safe and promising for 
enhancing cognition, this drug was studied in schizophrenic 
patients to determined whether the 7 nAChRs activation is 
responsible for the normalization of the P50 auditory evoked 
potential deficits in schizophrenia [102]. Additionally, the 
safety and effects of DMXB-A on neurocognition in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Chemical structures of anabaseine, anabasine, DMXB-A, DMAB, DMAC and 4-OH DMXB-A. 
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schizophrenia patients were also evaluated. DMXB-A was 
administered in a double-blind, placebo-controlled cross-
over design to 12 male and female non-smokers with 
schizophrenia. DMXB-A was administered orally (150 or 75 
mg) followed 2 h later by a half dose (75 or 37.5 mg). 
DMXB-A improved performance on both the repeatable 
battery for assessment for neuropsychological status 
(RBANS) total scale score and the attention scale. DMXB-A 
also normalized the P50 ratio as well as the test wave 
amplitude, a more specific measure of inhibition.  
  On the basis of this initial positive trial, a phase 2 trial 
was conducted to assess whether the cognitive effects would 
continue during longer-term administration and whether the 
clinical ratings would also change [103]. Thirty-one subjects 
with schizophrenia received DMXB-A at one of two 
different doses or a placebo for 4 weeks in a three-arm, two-
site, double-blind, crossover phase 2 trial. The doses were 
those used in the phase 1 trial. The Measurement and 
Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) Consensus Cognitive Battery developed by the 
National Institute of Mental Health was used to assess 
cognitive effects, and the Scale for the Assessment of 
Negative Symptoms (SANS) and Brief Psychiatry Rating 
Scale (BPRS) were used to assess the clinical effects. 
Subjects continued their current antipsychotic drug during 
the trial and were nonsmokers. There were no significant 
differences in the MATRICS cognitive measures between 
DMXB-A and placebo over the three treatment arms, but 
patients taking the higher DMXB-A dose experienced 
significant improvement in the SANS total score and nearly 
significant improvement in the BPRS total score. 
Improvement was most notable on the SANS anhedonia and 
alogia subscales. Examination of the first treatment arm 
showed effects of DMXB-A on the attention/vigilance and 
working memory MATRICS domains, compared to baseline. 
There were, however, increased reports of nausea and 
restlessness during DMXB-A treatment. Nausea occurred in 
patients (45%) at the higher dose of DMXB-A, suggesting 
the known effects of nicotinic agonists on gastrointestinal 
motility [103]. Considering the high incidence of nausea in 
the treatment with 7 nAchR agonists, 7 nAchR agonists 
with 5-hydroxytryptamine-3 (5-HT3) receptor antagonism 
would be potential therapeutic drugs for cognitive 
impairments as well as negative symptoms in schizophrenic 
patients, since the 5-HT3 receptor antagonists have been used 
for the treatment of nausea [104]. 
AstraZeneca 
  Researchers at AstraZeneca reported the profile of AR-
R17779, ()-spiro[1-azabicyclo[2.2.2]octane-3,5-oxazolidin 
-2-one] (Fig. 4), a potent full agonist of the 7 nAChRs that 
is highly selective for the 7 subtype over the 42 subtypes 
[105]. AR-R17779 has been widely used as a selective full 
agonist of the 7 nAChRs. For example, AR-R17779 failed 
to stimulate locomotor activity in both nicotine-nontolerant 
and -sensitized rats, whereas nicotine and the putative 
agonist SIB1765F, [±]-5-ethynyl-3-(1-methyl-2-pyrrolidiny-
l)pyridine fumarate (Fig. 4) [100], of 42 nAChRs 
increased the activity under both experimental conditions, 
suggesting a negligible role of 7 nAChRs in nicotine-
induced hyperlocomotion and reward in the rat [106]. 
Furthermore, it has been reported that chronic administration 
of both nicotine and SIB1765F, but not AR-R17779, resulted 
in an enhanced locomotor response to acute challenge with 
either nicotine or SIB1765F but not AR-R17779, suggesting 
that the 42 subtype plays a role in both the initiation and 
expression of sensitization to the psychomotor stimulant 
effects of nicotine [107]. Moreover, administration of AR-
R17779 improved learning in two radial-arm maze tasks and 
reversed working memory impairment caused by fimbria-
fornix section [108]. These findings suggest that 7 nAChRs 
play a role in learning and memory, and that agonists of 7 
nAChRs might have therapeutic potential for cognitive 
impairments in neuropsychiatric diseases, including 
schizophrenia. 
  Very recently, researchers at AstraZeneca reported that a 
furopyridine, (2R)-spiro-[1-azabicyclo[2.2.2]octane-3,2(3H)-
furo[2,3-b]pyridine  D-tartrate (AZD0328; Fig. 4), was a 
novel selective partial agonist for an 7 nAChR [109]. 
AZD0328 exhibited high affinity for the native rat (Ki=4.7 
nM) and recombinant human (Ki=3.0 nM) 7 nAChR, 
respectively. ADZ0328 also exhibited high affinity for both 
native rat (Ki=25 nM) and recombinant human (Ki=12 nM) 
5-HT3  receptors. In contrast, AZD0328 exhibited only 
moderate affinity for the 42 nAChR of the native rat 
(Ki=140 nM) and very low affinity for the “ganglionic” 3 
subunit-containing (Ki=2,500 nM) and muscle 11 
nAChR (Ki=20,000) of the mouse. Functional assay revealed 
the partial agonistic nature of AZD0328. The half maximal 
(50%) effective concentration (EC50) and intrinsic activity of 
AZD0328 were 150 nM and 61% for rat 7 nAChR and 338 
nM and 65% for human 7 nAChR, respectively. Adminis-
tration of a low dose (0.00138 mg/kg) of AZD0328 in vivo 
leads to a significant increase in the excitability of midbrain 
dopaminergic neurons with no independent change in the 
spike patterns produced by these neurons. Within the same 
dose range, AZD0328 led to a significant increase in cortical 
dopamine release and improved both conditioned response 
learning and memory retention in an object recognition task. 
These effects were blocked by the selective 7 nAChR 
antagonist MLA (Fig. 2). AZD0328 improved novel object 
recognition in mice over a broad range of doses 
(0.001781.78 mg/kg) and the compound effect was found 
to be absent in homozygous 7 nAChR-knockout mice. 
 
 
 
Fig. (4). Chemical structures of AR-R17779, SIB1765F, and AZD0328. 
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Together, these data indicate that selective interaction with 
7 nAChRs by AZD0328 selectively enhances midbrain 
dopaminergic neuronal activity, causing an enhancement of 
cortical dopamine levels; these neurochemical changes, in 
turn, likely underlie the positive behavioral responses 
observed in the two different animal models. These results 
also suggest that selective 7 nAChR agonists may have 
significant therapeutic utility in neurologic and psychiatric 
disorders in which cognitive effects and dopamine neuron 
dysfunction co-exist. 
Mitsubishi Tanabe 
  Macor and Wu [110] reported some derivatives of 1-
azabicyclo[2.2.2]oct-3-yl phenylcarbamate as agonists of 7 
nAChRs (Fig. 5). In order to develop novel agonists of 7 
nAChRs, researchers at Mitsubishi Pharma Corporation 
(currently Mitsubishi Tanabe Pharma Corporation) hypothe-
sized that 1-azabicyclo[2.2.2]octane derivatives, bearing an 
aromatic part and a spacer group at the 3-position, may 
exhibit agonist activity at 7 nAChRs [111]. By examining a 
series of 3-substituted 1-azabicyclo[2.2.2]octane derivatives, 
they found that (+)-3-[2-(benzo[b]thiophen-2-yl)-2-oxo-
ethyl]-1- azabicycle[2.2.2]octane was a potent and partial 
agonist of 7 nAChRs (Fig. 5) [111]. Furthermore, they 
reported the structure-activity relationships and pharmaco-
kinetic profiles of the series of compounds leading to the 
discovery of (R)-3(5-chlorothiophen-2-yl)spiro-1-
azabicyclo[2,2,2]octane-3,5-[1,3]oxazolidin-2-one (Fig. 5) 
[112]. This compound has potent binding affinity (Ki=9 nM 
for  7 nAChRs) and good selectivity toward the other 
nicotinic subtypes (42 and 12). Also, this compound 
has good oral bioavailability and brain permeability. 
Interestingly, this compound (10 mg/kg, p.o.) significantly 
improved dizocilpine (3 mg/kg)-induced auditory gating 
deficits in rats, suggesting that this compound has the 
potential to improve sensory gating deficits in schizophrenic 
patients [112]. Moreover, they have developed a novel 
partial 7 nAChR agonist, W-56203, (R)-3-(3-methylbenzo-
[b]thiophen-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,5-oxazo-
lidin]-2-one (Fig. 5) [113]. W-56203 bound to 7 nAChRs 
with a Ki value of 3 nM. No significant binding of W-56203 
was detected at 42 nAChRs or muscarinic receptors. 
Furthermore, W-56203 showed no binding to other known 
receptors (dopamine D1 and D2, 5-HT1A, 5-HT2, adrenergic 
1, 2, histamine H1 and H2) or ion channels (NMDA and 
-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA)), although W-56203 exhibited a moderate affinity 
to 5-HT3 receptors. In cultured hippocampal neurons, W-
56203 evoked a rapidly desensitizing inward current, which 
was blocked by the selective 7 nAChR antagonist MLA (1 
nM) (Fig. 2). Interestingly, W-56203 has been shown to 
significantly improve dizocilpine-induced auditory gating 
deficits in rats [113]. These results suggest that W-56203 is 
an orally active and partial agonist of 7 nAChRs, and that 
W-56203 would be a potential drug for the treatment of 
schizophrenia. 
Targacept 
  Researchers at Targacept Inc. reported that 2-(3-pyridyl)-
1-azabicyclo[3.2.2]nonane (TC-1698; Fig. 6) was a highly 
selective agonist of 7 nAChRs [114]. TC-1698 exhibited a 
Ki of 11 nM in the binding assay of [
3H]MLA to rat 
hippocampal membranes, whereas TC-1698 (10 μM) had no 
or very low affinity for other receptors. TC-1698 exerts 
neuroprotective effects via activation of the JAK2/PI3K 
cascade, which can be neutralized through activation of the 
angiotensin II receptors [114]. These findings suggest that 
JAK2 plays a central role in the 7 nAChR activation of the 
JAK2-PI3K cascade in PC12 cells, which ultimately 
contribute to 7 nAChR-mediated neuroprotection. 
  They further synthesized a series of 2-(arylmethyl)-3-
substituted quinuclidines as 7 nAChR agonists based on a 
putative pharmacophore model [115]. Quinuclidine is a well 
established pharmacophoric element. Its basic nitrogen, 
occupying a bridgehead position within an azabicyclic 
system, allocates the maximal electrostatic interaction 
combined with minimal steric demand. To further define 
pharmacophoric elements, they conducted virtual and 
synthetic diversification around a combination of 2-position 
and 3-position substitutions of the quinuclidine scaffold. 
This effort revealed the presence of three pharmacophoric 
elements: the cationic site (quinuclidine nitrogen), a 
 
 
 
 
 
 
 
 
 
Fig. (5). Chemical structures of 1-Azabicyclo[2.2.2]oct-3-yl phenylcarbamate derivatives, (+)-3-[2-(benzo[b]thiophen-2-yl)-2-oxoethyl]-1- 
azabicycle[2.2.2]octane, (R)-3(5-chlorothiophen-2-yl)spiro-1-azabicyclo[2,2,2]octane-3,5-[1,3]oxazolidin-2-one, and W-56203. 
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hydrogen bond acceptor at the 3-position, and another 
hydrogen bond acceptor at the 2-position (the pyridine ring). 
In position 2 of quinuclidine, heteroarylmethyl groups are 
favored over benzyl, and steric constraints restrict 
substitution on the heteroaryl (pyridine) ring. The 
pharmacophoric element in position 3 was most amenable to 
diversification, resulting in the generation of four classes of 
ligands: carbamates, ureas, amides and sulfonamide. Cis-
configuration is favorable for binding to the receptor. Within 
the 3-position substituent, a comparison of aliphatic and 
aromatic groups suggested that -interaction may play a 
significant role in increasing affinity. As a result, several 
synthesized compounds exhibited high affinity to the 7 
nAChR with Ki values near or below 1 nM. None of these 
compounds bound to 42 receptors with any significant 
affinity (Ki>10 μM). Among these series of compounds, N-
{(2R,3R)-2-[(pyridin-3-yl)methyl]quinuclidin-3-yl}benzofu-
ran-2-carboxamide (TC-5619; Fig. 6) has potent full 
agonistic activity for the 7 nAChR (EC50=33 nM, agonist 
activity=100), at a concentration below those that result in 
desensitization. Hauser et al. [116] further characterized the 
pharmacological properties of TC-5619. TC-5619 binds with 
very high-affinity to the 7 nAChR of the native rat 
hippocampus (Ki=1 nM) and the 7 nAChR of human HEK 
7/RIC3 cells (Ki=1 nM), respectively. TC-5619 has little or 
no activity at other nicotinic receptors, including the 42 
(Ki=2,800 and 2,100 nM for rat cortex and human SH-EP1 
cells, respectively), ganglionic (34) and muscle subtypes. 
In a transgenic th(tk)/th(tk) mouse model that reflects 
many of the developmental, anatomical, and multi-
transmitter biochemical aspects of schizophrenia, TC-5619 
acted both alone and synergistically with the antipsychotic 
clozapine to correct impaired pre-pulse inhibition (PPI) and 
social behaviors which model positive and negative 
symptoms, respectively. Similar to the results in the 
transgenic mice, TC-5619 significantly reversed the 
apomorphine-induced PPI deficits in rats. In a novel object-
recognition paradigm in rats, TC-5619 demonstrated long-
lasting enhancement of memory over a wide dose range. 
These findings suggest that TC-5619, either alone or in 
combination with antipsychotics, could offer a new approach 
to treating the constellation of symptoms associated with 
schizophrenia, including cognitive dysfunction. A phase 1 
single rising dose (10900 mg) clinical trial of TC-5619 in 
66 healthy volunteers showed that TC-5619 was generally 
well tolerated up to doses of 600 mg
*. A multiple dose 
                                                 
* Lippiello, P. TC-5619: An 7 nAChR selective agonist with efficacy in animal 
models of positive and negative symptoms, and cognitive dysfunction of schizophrenia. 
(10300 mg) administered for 10 days in 38 young healthy 
volunteers achieved significant improvements in the clinical 
dementia rating (CDR) test. A phase 2 proof-of-concept 
study will start at 4Q 2009 in patients with AD and attention 
deficit hyperactivity disorder (ADHD). 
Pfizer 
  Researchers at Pfizer reported on the selective 7 
nAChR agonist PNU-282987, N-[(3R)-1-azabicyclo[2.2.2]-
oct-3-yl]-4-chlorobenzamide hydrochloride (Fig. 7) [117, 
118]. PNU-282987 binds to 7 nAChR with a Ki of 27 nM, 
and showed evoked whole-cell currents from cultured rat 
hippocampal neurons that were sensitive to the selective 7 
nAChR antagonist MLA [117, 118]. Systemic administration 
of PNU-282987 (1 mg/kg, i.v.) significantly improved d-
amphetamine-induced sensory gating deficits in chloral 
hydrate-anesthetized rats. These findings suggest that PNU-
282987 may be useful for treating the cognitive and 
attentional deficits of schizophrenia [117, 118]. This 
compound was later found, however, to possess significant 
human ether-a-go-go (hERG) potassium channel activity and 
thus did not meet Pfizer’s criteria for further development. 
Additional work on this template demonstrated that fused 
6,5-heterocyclic analogues, such as indole (Fig. 7), provided 
an avenue toward novel analogues with potential for 
improved safety profiles. Of the 6,5-fused heterocycles 
evaluated,  N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]py-
ridine-5-carboxamide (PHA-543613; Fig. 7) proved to be a 
potent, high-affinity agonist of the 7 nAChR (Ki=8.8 nM: 
7-5-HT3 chimera EC50=65 nM) [119]. PHA-543613 
possesses antagonist activity at the 5-HT3 receptor (Ki=628 
nM). PHA-543613 showed no detectable agonist activity 
(>100 μM) and negligible antagonist activity at both muscle-
like nAChRs and ganglion-like nAChRs. Further, this 
furopyridine derivative did not significantly displace tritiated 
cytisine from rat brain homogenate at 1 μM, suggesting a 
selectivity over the 42 nAChR. The excellent in vitro 
profile of PHA-543613 is matched by rapid brain 
penetration, high oral bioavailability in rats, and a favorable 
hERG profile. Furthermore, PHA-543613 demonstrated 
efficacy in two in vivo models, the reversal of an 
amphetamine-induced P50 gating deficit (0.3 mg/kg, i.v.), 
and improved performance in a novel object-recognition test 
(1.0 mg/kg, s.c.).  
  While further evaluation of PHA-543613 was underway, 
researchers at Pfizer identified additional novel, potent (<50 
nM), and selective 7 nAChR agonists that, like PHA-
543613, possess reduced hERG activity and low first pass 
metabolism [120]. To expand the SAR on the quinuclidine 
amide template and gain a broader understanding of the 
overlap with other nicotinic pharmacophores, two parallel 
approaches were utilized. The first focused on the acid 
portion of the quinuclidine template (amine part). The 
second approach investigated modifications to the 
azabicyclic ring system (acid part). The best compounds 
from each series are characterized by rapid brain penetration, 
good oral bioavailability in rats, and in vivo efficacy in a rat 
P50 auditory sensory gating assay. Finally, the researchhers 
discovered 2,3-dihydro-N-[(R)-quinuclidin-3-yl]benzo[b]-
                                                                                  
Nicotinic acetylcholine receptors as therapeutic targets: emerging frontiers in basic 
research and clinical science; Chicago, IL, Oct. 14-Oct. 17, 2009. 
 
 
 
 
 
Fig. (6). Chemical structures of TC-1698 and TC-5619. 
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[1,4]dioxine-6-carboxamide (PHA-568487; Fig. 7), which 
showed an improved hERG safety profile over PHA-543613. 
However, these two phase, I clinical candidates (PHA-
543613 and PHA-568487) were discontinued due to 
cardiovascular findings.
† 
  Very recently, researchers at Pfizer disclosed the 
synthesis of (3R,  5R)-1-azabicyclo[3.2.1]octane-3-amine 
dihydrochloride (Fig. 8) and demonstrated that the activity of 
the corresponding para-chlorobenzamide (Fig. 8) in a 7-5-
HT3 chimera assay was equal to that of the potent 7 nAChR 
agonist, PNU-282987. To identify novel, potent and orally 
bioavailable 7 nAChR agonists with in vitro and in vivo 
potential equal or better than that of PHA-543613, they 
proceeded to synthesis of an expanded set of amides derived 
from amine [121]. Among them, the furopyridine derivative 
                                                 
† Rogers, B.N. Agonists of 7 nAChRs for the potential treatment of cognitive deficits 
in Schizophrenia. Nicotinic acetylcholine receptors as therapeutic targets: emerging 
frontiers in basic research and clinical sciences; San Diego, CA, Oct. 31-Nov. 2, 2007. 
N-[(3R,5R)-1-aza-bicyclo[3.2.1]octan-3-yl]furo[2,3-c]pyri-
dine-5-carboxamide (PHA-709829; Fig. 8), which is a 
structurally similar analog of PHA-543613, showed very 
similar activity in the 7-5-HT3 chimera functional assay 
(EC50=81 nM) and similar affinity in the 7 binding assay 
(Ki=2.9 and 3.9). PHA-709829 showed stability in rat liver 
microsomes comparable to that of PHA-543613. PHA-
709829 showed excellent CNS penetration in a brain 
delivery assessment screen (MDCK cell permeability, mouse 
brain/plasma ratio, Pgp substrate), displaying a profile very 
similar to PHA-543613. 
  Researchers at Pfizer also identified 1,4-
diazabicyclo[3.2.2]nonane phenyl carbamate (compound 
7aa; Fig. 8) as subtype selective, high affinity 7 agonist 
(Ki=23 nM, agonist activity =175%). The pharmacological 
profiles  of  this  compound  closely  resembled  that  of             
4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate 
hydrochloride (SSR180711; Fig. 9). The advantage of 
 
 
 
 
 
 
 
Fig. (7). Chemical structures of PNU-282987, N-[(R)-quinuclidin-3-yl]-1H-indole-6-carboxamide, PHA-543613, and PHA-568487. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Chemical structures of (3R,5R)-1-aza-bicyclo[3.2.1]octan-3-amine dihydrochloride, para-chlorobenzamide derivatives of (3R,5R)-1-
aza-bicyclo[3.2.1]octan-3-amine, PHA-709829, compound 7aa, and CP-801,123. 
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compound 7aa was that it showed the potential for an 
improved cardiosafety profile due to its low affinity for 
hERG. 
N N O
O
Br
SSR180711  
Fig. (9). Chemical structure of SSR180711. 
 
  Very recently, they reported the benzoxyazole derivative 
2-(5-methyloxazolo[4,5-b]pyridin-2-yl)-2,5-diaza-bicyclo[3. 
2.2]nonane (CP-810,123; Fig. 8) as a novel 7 nAChR 
agonist.
‡ This compound showed low affinity for hERG 
(IC50=40,000 nM) and high affinity binding to 7 nAChR. 
CP-810,123 has an excellent brain penetration and slow 
clearance from plasma and has shown marked ex vivo 
binding to cerebral binding sites (ED50=0.34 mg/kg). CP-
810,123 also showed favorable preclinical findings in a 
number of animal models of cognition and was therefore 
advanced into clinical trials. However, the multiple-dose, 14-
day clinical trial of CP-810,123 did not achieve any 
improvement of cognition at any of the doses tested, and was 
discontinued due to the occurrence of non-sustained 
ventricular tachycardia. 
Sanofi-Aventis 
  Researchers at Sanofi-Aventis demonstrated a novel 7 
nAChR agonist, SSR180711, 4-bromophenyl 1,4-
diazabicyclo[3.2.2]nonane-4-carboxylate hydrochloride (Fig. 
9) [122]. Binding assays show that SSR180711 has a high 
and selective affinity for the human (Ki=14 nM) and rat 
(Ki=22 nM) 7 nAChRs. This ligand inhibits, in a dose-
dependent manner, the ex vivo [
3H]-bungarotoxin binding 
in mouse cortical homogenates after both i.p. and p.o. 
administration. At recombinant human 7 nAChRs, 
SSR180711 displays a partial agonist profile. Furthermore, it 
has been reported that SSR180711 improves cognitive 
deficits in a variety of rat models related to schizophrenia 
[123]. This drug restores the selective attention deficit 
induced by phencyclidine (PCP) administration at the 
neonatal stage. This action is reversed by the 7 nAChR 
antagonist MLA. This drug also restores a short-term 
episodic memory impairment and a spatial working memory 
deficit induced by PCP or dizocilpine.  
 Hashimoto  et al. [124] reported that repeated 
administration of PCP significantly decreased the density of 
7 nAChRs in the mouse brain. In addition, Hashimoto et al. 
[124] reported that SSR180711 could ameliorate cognitive 
deficits in mice after repeated administration of PCP, and 
that these effects could be blocked by the co-administration 
of MLA. Furthermore, Thomsen et al. [125] reported that 
repeated co-administration of SSR180711 (3 mg/kg) with 
PCP prevented both changes of parvalbumin and 
                                                 
‡ O’Donnell, C.J. CP-810,123 a third generation alpha-7 nAChR agonist for treatment 
of cognitive deficits associated with schizophrenia. Nicotinic acetylcholine receptors as 
therapeutic targets: emerging frontiers in basic research and clinical science; Chicago, 
IL, Oct. 14-Oct. 17, 2009. 
 
synaptophysin, which correspond to changes seen in patients 
with schizophrenia, and changes in the level of Arc, a 
molecule involved in synaptic plasticity, mRNA expression 
in the prefrontal cortex, and the behavioral impairment 
induced by PCP. Moreover, Barak et al. [126] reported that 
SSR180711 potentiated latent inhibition (LI) in normal rats 
and reversed amphetamine-induced LI disruption, two 
models considered predictive of activity against positive 
symptoms of schizophrenia [127, 128]. It was also reported 
that increase of expression of immediate early genes in the 
frontal cortex and nucleus accumbens has been demonstrated 
after administration with SSR180711 [129, 130]. Søderman 
et al. [131] reported that acute systemic administration of 
SSR180711 (10 mg/kg) resulted in a significant increase in 
Fos protein levels in the shell of the nucleus accumbens in 
wild-type mice, but had no effect in the A1-42 
overexpressing transgenic mice. This result suggests that 
overexpression of human A peptides inhibits 7 nAChR-
dependent neurotransmission in vivo, perhaps via direct 
interaction with 7 nAChR, and underscores that clinical 
trials testing 7 nAChR agonists should be related to the 
content of A peptides in the patient’s nervous system. 
  Taken together, these findings suggest that SSR180711 
has the potential to improve cognitive deficits associated 
with schizophrenia and AD.  
WYETH/SIENA BIOTECH 
  Based on an initial hit identified in a screening program, 
researchers at Wyeth Research and Siena Biotech SpA 
obtained a novel 7 nicotinic acetylcholine receptor agonist, 
5-morpholino-4-yl-pentanoic acid (4-pyridn-3-yl-phenyl)-
amide (SEN12333/WAY-317538; Fig. 10), as the result of a 
structure-activity relationship study [132]. SEN12333/WAY-
317538 shows high affinity for the rat 7 receptor expressed 
in GH4C1 cells (Ki=260 nM) and acts as a full agonist in 
functional Ca
2+  flux studies (EC50=1.6  μM). 
SEN12333/WAY-317538 did not show agonist activity at 
the other nicotinic receptor subtypes tested (1 and 42) or 
at highly homologous receptors (5-HT3A). SEN12333/WAY-
317538 acted as a weak antagonist at 3-containing 
receptors and histamine H3 receptors. At a concentration of 
10 μM of SEN12333/WAY-317538, no detectable inhibition 
binding was measured for the neurotransmitter and bioactive 
peptide receptors. SEN12333/WAY-317538 also showed 
minimal hERG inhibition, and desirable drug-like (molecular 
weight, number of rotatable bonds, log P, polar surface area) 
and pharmacokinetic properties. In vivo, SEN12333/WAY-
317538 treatment (3 mg/kg i.p.) improved episodic memory 
in a novel object-recognition task in rats under the conditions 
of spontaneous forgetting and cognitive disruptions induced 
via glutamatergic (dizocilpine) or cholinergic (scopolamine) 
mechanisms [133]. This improvement was blocked by the 7 
nAChR antagonist MLA. SEN12333/WAY-317538 also 
prevented a scopolamine-induced deficit in a passive 
avoidance task. In models targeting other cognitive domains, 
including attention and perceptual processing, SEN-
12333/WAY-317538 normalized the apomorphine-induced 
deficit of PPI. Neuroprotection of SEN12333/WAY-317538 
was demonstrated in quisqualate-lesioned animals in which 
treatment with SEN12333/WAY-317538 (3 mg/kg/day i.p.) 
resulted in a significant protection of choline 
acetyltransferase-positive neurons in the lesioned 46    The Open Medicinal Chemistry Journal, 2010, Volume 4  Toyohara and Hashimoto 
hemisphere. Cumulatively, these results demonstrate that the 
novel  7 nAChR agonist SEN12333/WAY-317538 has 
precognitive and neuroprotective properties. 
  Very recently, researchers at Wyeth reported the novel 
selective 7 nAChR agonist 1-[6-(4-fluorophenyl)pyridin-3-
yl]-3-[4-(piperidin-1-yl)butyl]urea (WYE-103914/SEN34625; 
Fig.  10).
§  WYE-103914/SEN34625 bound with high 
affinity to a rat 7 nAChR expressed in GH4C1 cells with a 
Ki of 44 nM and increased intracellular Ca
2+ with an EC50   
of 130 nM (activity=99%). WYE-103914/SEN34625 was 
>100-fold selective against 1, 3, 4/2 nAChRs receptors 
and the 5-HT3 receptor. In a rat novel object-recognition 
procedure, WYE-103914/SEN34625 (1 mg/kg, p.o.) trea-
tment produced statistically significant enhancement of 
visual learning and memory retention, and this effect was 
blocked by pretreatment with MLA (5 mg/kg, i.p.). Pre-
treatment with WYE-103914/SEN34625 reversed the me-
mory disrupting effects of dizocilpine (10 mg/kg, p.o.) in 
rats. WYE-103914/SEN34625, administered concurrently 
with dizocilpine immediately after training, produced a 
statistically significant reversal of dizocilpine-disrupted 
social odor recognition in mice at 3 mg/kg, p.o. In addition, 
WYE-103914/SEN34625 administered immediately follow-
ing training enhanced retention memory in social odor 
recognition evaluated 6 days later (10 mg/kg, p.o.). 
Treatment with 3 mg/kg/day i.p. of WYE-103914/SEN34625 
for 7 days also attenuated the decrease in the number of 
choline acetyltransferase-positive neurons produced by the 
injection of quisqualic acid into the nucleus basalis 
magnocellularis. These data indicate that WYE-103914/ 
SEN34625 exhibits a robust preclinical cognitive-enhancing 
and potentially neuroprotective profile. 
Bayer 
  Researchers at Bayer reported the profile of the novel 7 
nAChR agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-
(methoxy)phenyl]-1-benzofuran-2-carboxamide (ABBF; Fig. 
11) [134]. ABBF bound to 7 nAChR in rat brain 
membranes (Ki=62 nM) and to recombinant 5-HT3 receptors 
(Ki=60 nM), and thus its agonistic activity was appro-
ximately 50-fold more potent than that of the natural agonist 
ACh (Ki=3  μM) and 10-fold more potent than nicotine 
(Ki=770 nM). ABBF was a potent agonist at the recombinant 
rat and human 7 nAChR expressed in Xenopus oocytes, but 
it did not show agonist activity at other nAChR subtypes. 
                                                 
§ Dunlop, J.; Comery, T.A.; Lock, T.; Kramer, A.; Kowal, D.; Yeola, S.; Jow, F.; 
Aschmies, S.; Lin, Q.; Beyer, C.E.; Brennan, J.; Kelly, C.; Roncarati, R.; Scali, C.; 
Haydar, S.; Ghiron, C.; Marquis, K.L.; Harrison, B.; Robichaud, A.; Terstappen, G.C. 
In vitro pharmacological characterization and pro-cognitive effects of the selective 
alpha-7 nicotinic agonist WYE-103914. Biochem. Pharmacol., 2009, 78, 911. 
ABBF acted as an antagonist of the 5-HT3 receptor and 
34, 42, and muscle nAChRs. ABBF improved social 
recognition memory in rats (0.31 mg/kg, p.o.). This 
improvement was blocked by intracerebroventricular 
administration of the 7 nAChR antagonist MLA (10 μg). In 
addition, ABBF improved the working memory of aged rats 
in a water maze repeated acquisition paradigm (1 mg/kg, 
p.o.) and object-recognition memory in mice (0.31 mg/kg, 
p.o.). Moreover, rats trained to discriminate nicotine (0.4 
mg/kg, s.c.) from vehicle did not generalize to ABBF 
(0.330 mg/kg, p.o.), suggesting that the nicotine cue is not 
mediated by the 7 nAChRs and that selective 7 nAChR 
agonists may not share the abuse liability of nicotine. These 
results support the hypothesis that 7 nAChR agonists might 
provide a novel therapeutic strategy for the treatment of 
cognitive deficits with low abuse potential. 
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Fig. (11). Chemical structure of ABBF. 
 
Abott Laboratories 
  As mentioned above, the most recently described 7 
agonists are derived from the quinuclidine structural class. 
Alternatively, researchers at Abott Laboratories identified 
2,7-bis(2-(diethylamino)ethoxy)-9H-fluoren-9-one (Tilorone; 
Fig. 12) as a lead structure for a novel 7-selective agonist 
and developed related tricyclic analogs [135]. The lead 
structure tilorone bound 7 nAChR (IC50=110 nM) with 
high selectivity relative to 42 (IC50=70,000 nM), activated 
human  7 nAChR with an EC50 value of 2.5 μM and 
maximal response of 67% relative to ACh, and showed little 
agonist effect at human 34 or 42 nAChRs. However, 
the rat 7 nAChR maximal response was only 34%. Lead 
optimization led to 2-(5-methyl-hexahydro-pyrrolo[3,4-
c]pyrrol-2-yl)-xanthen-9-one (A-844606; Fig. 12) with 
improved binding (7: IC50=11 nM; 42: IC50>30,000 nM) 
and activity at both human and rat 7 nAChRs (EC50s=1.4 
and 2.2 μM, respectively; apparent efficacies=61% and 
63%). These compounds also activated native 7 nAChR, 
stimulating extracellular signal-regulated kinase 1/2 
(ERK1/2) phosphorylation in PC12 cells. These findings 
suggest that tilorone, known as an interferon inducer, is a 
selective  7 nAChR agonist, and that the fluorene 
 
 
 
 
Fig. (10). Chemical structures of SEN12333/WAY-317538 and WYE-103914/SEN34625. 
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pharmacophore would be useful for the development of 
selective  7 nAChR agonists. Whether 7 nAChR 
stimulation mediates interferon induction, or whether 
interferon induction may influence the potential anti-
inflammatory properties of 7 nAChR agonists remains to 
be elucidated.  
  Researchers at Abbott Laboratories also reported a novel 
biaryl diamine 7 nAChR agonist, 2-methyl-5-(6-
phenylpyridazin-3-yl)octahydropyrrolo[3,4-c]pyrrole (A-
582941; Fig. 12). A-582941 was found to exhibit high-
affinity binding to native rat (Ki=10.8 nM) and human 
(Ki=16.7 nM) 7 nAChRs [136, 137]. In contrast, A-582941 
showed substantially weaker binding (Ki>100 μM) to 4, 
3, and 1 subunit-containing nAChRs, respectively. 
Furthermore, A-582941 (10 μM) did not show significant 
displacement of binding of >75 targets (multiple G-protein-
coupled receptors, ligand- and voltage-gated ion channel 
binding sites, acetylcholine esterase, and muscarinic 
receptors) with the exception of 5-HT3 receptors (Ki=154 
nM). A-582941 showed partial agonism at Xenopus oocytes 
expressing human 7 nAChRs (EC50=4.26  μM; 
activity=52%) [137]. A-582941 showed acceptable 
pharmacokinetic properties and excellent distribution to the 
CNS in rodents. For example, intraperitoneal (i.p.) 
administration of A-582941 (1 μmol/kg) in mice produced 
maximal levels in the brain (286 ng/g at 0.33 h) that were 
11-fold higher than the maximum plasma concentration (26 
ng/mL at 0.25 h). This distribution ratio was maintained over 
an 8 h period, as the drug cleared from the brain and plasma 
with t1/2 = 2.53.2 h. Similarly, in rats, A-582941 distributes 
with approximately 6-fold higher levels in the brain than the 
plasma after i.p. dosing at 220  μmol/kg. Over this dose 
range, linear pharmacokinetics were observed, with the brain 
Cmax (normalized to a 1 μmol/kg dose) averaging 363 ng/g 
and maximum plasma levels of 62 ng/mL. A-582941 
enhanced cognitive performance in behavioral assays 
including the monkey delayed matching-to-sample, rat social 
recognition, and mouse inhibitory avoidance models, which 
capture domains of working memory, short-term recognition 
memory, and long-term memory consolidation, respectively. 
In addition, A-582941 normalized the sensory gating deficits 
induced by the 7 nAChR antagonist MLA in rats, and in 
DBA/2 mice that exhibit a natural sensory gating deficit. In 
vitro and in vivo studies indicated that A-582941 activates 
signaling pathways known to be involved in cognitive 
functions such as ERK1/2 and cAMP response element-
binding protein (CREB) phosphorylation [137]. A-582941 
exhibited a benign secondary pharmacodynamic and tolera-
bility profile as assessed in a battery of assays of 
cardiovascular, gastrointestinal, and CNS function. A-
582941 was non-mutagenic in the Ames reverse mutation 
assay in 5 bacterial strains, even with metabolic activation by 
a microsomal S9 fraction. The predominant adverse effects 
of A-582941, observed at doses substantially greater than 
those shown to be effective in cognition models, include 
clinical signs of CNS activity (tremors). Emesis and 
cardiovascular effects are of relatively minor concern. 
Although moderate QTc prolongation is observed with A-
582941 in dogs at high plasma exposures, it does not appear 
to be 7-related. Investigation of potential carcinogenic 
effects produced no significant findings to suggest any 7-
related toxicity. The details of the preclinical validation 
studies of A-582941 were recently reported [138]. Very 
recently, Biter et al. [139] reported that A-582941 can lead 
to increased phosphorylation of the inhibitory regulating 
amino acid residue Ser-9 on the glycogen synthase kinase3 
(GSK3), a major kinase responsible for tau hyper-
phosphorylation in the neuropathology of tauopathies such 
as front-temporal dementia and AD. A-582941 increased 
Ser-9 phosphorylation of GSK3 in the mouse cingulate 
cortex and hippocampus, and this increase in phos-
phorylation was not observed in 7 nAChR-knockout mice. 
Moreover, A-582941 continuous infusion decreased the 
phosphorylation of tau in hippocampal CA3 mossy fibers 
and spinal motoneurons in a hypothermia-induced tau 
hyperphosphorylation mouse and AD double transgenic 
APP/tau mouse model, respectively. 
  Very recently, researchers at Abbott Laboratories 
reported a series of 5-(pyridine-3-yl)octahydropyrrolo[3,4-
c]pyrroles as a diamine scaffold for constitution of either 
42 or 7 selective nAChR ligands [140]. In that article, 
they identified the most potent (agonist activity=87%) and 
 
 
 
 
 
 
 
 
 
Fig. (12). Chemical structure of Tilorone, A-844606, A-582941, and compound 46. 
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selective (Ki for 7=0.24 nM; >400,000-fold selective for 
42)  7 ligand in this series as 5-{6-[(3aS,6aR)-
hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]pyridazin-
3-yl}-1H-indole (compound 46; Fig. 12). 
Novartis 
  Researchers at Novartis reported a novel selective 7 
nAChR agonist, (S)-(1-azabicyclo[2.2.2]oct-3-yl)-carbamic 
acid (S)-1-(2-fluoro-phenyl)-ethyl ester (JN403; Fig. 13) 
[141]. JN403 displayed high affinity for human recombinant 
7 nAChR (Ki=200 nM). Ki values were estimated from the 
original pKD data. JN403 showed lower affinity for two 
other recombinant nAChR subtypes, human 34 (Ki=6,309 
nM) and human 42 (Ki=158,489 nM). JN403 also showed 
low affinity toward the native murine 5-HT3 receptor 
(Ki=12,589 nM). Further, JN403 showed selectivity over a 
wide range of neurotransmitter receptors, ion channels and 
transporters. A functional assay with Xenopus oocytes 
expressing human recombinant 7 nAChR showed the 
partial agonistic nature of JN403 (EC50=2.14  μM; agonist 
activity=55%).  
 Recently,  in vivo effects of JN403 were reported by 
researchers at Novartis [142]. JN403 rapidly penetrates into 
the brain after intravenous (i.v.) and after peroral (p.o.) 
administration in mice and rats. In the social recognition test 
in mice JN403 facilitates learning/memory performance over 
a broad dose range. JN403 shows anxiolytic-like properties 
in the social exploration model in rats and the effects are 
retained after a 6 h pre-treatment period and after subchronic 
administration. Systemic administration of JN403 restores 
sensory gating in DBA/2 mice, a strain with reduced sensory 
inhibition under standard experimental conditions. 
Furthermore, JN403 shows anticonvulsant potential in the 
audiogenic seizure paradigm in DBA/2 mice. In the two 
models of permanent pain tested, JN403 produces a 
significant reversal of mechanical hyperalegesia. Together, 
these data suggest that JN403 may be beneficial for 
improving learning/memory performance, restoring sensory 
gating deficits, and alleviating pain, epileptic seizures and 
conditions of anxiety. 
  The common pharmacophore of nicotine and 7 nAChR 
agonists usually consists of a strong base (e.g., pyrolidine in 
nicotine; piperidine or tetrahydropyridine in an anabasein-
derived scaffold; or a bicyclic amine, usually quinuclidine) 
connected to a hydrophilic element by a linker (e.g., 
carbamate, ether or amide). In view of the highly populated 
chemical space around these general scaffolds, researchers at 
Novartis discovered alternative templates. They found a cis 
-lactam scaffold and optimized it to reveal highly potent 
and selective 7 nAChR agonists with in vitro activity and 
selectivity and with good brain penetration in mice [143]. 
Among them, (3R,5S)-1-methyl-5-(2-phenylethynyl)-3-
[(piperidin-1-yl)methyl]pyrrolidin-2-one (compound 28) and 
(3R,5S)-5-[2-(benzofuran-5-yl)ethynyl]-1-methyl-3-[(piperi-
din-1-yl)methyl]pyrrolidin-2-one (compound 30) showed 
potent and selective 7 nAChR agonistic activity (Fig. 13). 
Compounds 28 and 30 displayed high affinity for human 
recombinant 7 nAChR (IC50=10 and 7.9 nM, respectively). 
The IC50 values were estimated from the original pIC50 data. 
At other recombinant nAChR subtypes, compounds 28 and 
30 showed lower affinity: human 34 (IC50=1,258.9 and 
1,000 nM, respectively); human 42 (IC50=7,943.3 and 
10,000 nM, respectively); human 11 (IC50=12,589.3 
and 6,309.6 nM, respectively). Compounds 28 and 30 also 
showed low affinity toward recombinant human 5-HT3 
receptors (IC50=251,188.6 and 50,118.7 nM, respectively). 
When tested against human recombinant muscarinic 
receptors, compounds 28 and 30 also displayed an IC50>10 
μM on all subtypes (M1M5). Compound 28 showed rapid 
clearance, but the brain/plasma ratios remained high at 1 and 
4 h after treatment with 30 μmol/kg p.o.. Compound 30 
improved the in vivo pharmacokinetic properties. High brain 
and plasma levels were observed at 1 and 4 h following 
administration. Additionally, these compounds displayed 
good cardiosafety profiles. Taken together, these findings 
indicate that these new scaffolds, which are devoid of the 
classical bicyclic amine, will provide a valuable lead series 
for further development. 
Eli Lilly 
  Researchers at Eli Lilly found several high affinity 
ligands for 7 nAChRs with no/small 5-HT3 receptor cross-
reactivity [144]. For example, N-(quinuclidin-3-yl)-5-
(thiophen-2-yl)thiophene-2-carboxamide (compound 8; Fig. 
14) showed a potent 7 ligand (Ki=1.1 nM) and still had 
1,000-fold selectivity for 7 nAChRs over 5-HT3 receptors. 
Additionally, 5-phenyl-N-[(R)-quinuclidin-3-yl]thiophene-2-
 
 
 
 
 
 
 
 
Fig. (13). Chemical structure of JN403, compound 28, and compound 30. 
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carboxamide (compound 7a; Fig. 14) also showed a potent 
7 ligand (Ki=1.8 nM) and high selectivity for 7 nAChRs 
over 5-HT3 receptors (5-HT3 receptor Ki: 24% at 10 μM). 
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Fig. (14). Chemical structure of compound 8 and compound 7a. 
 
MEMORY PHARMACEUTICALS/ROCHE 
  Researchers at Memory Pharmaceuticals reported a novel 
7 nAChR partial agonist and 5-HT3 receptor antagonist, 
R3487/MEM3454 [145]. The chemical structure of 
R3487/MEM3454 was not disclosed, and the compound is 
currently being developed by Roche as RO5313534 [146]. 
R3487/MEM3454 is an orally active 7 nAChR agonist with 
high affinity for native rat 7 nAChRs (Ki=6 nM). 
R3487/MEM3454 also showed a similar high affinity 
binding to human recombinant 5-HT3 receptors (Ki=2 nM). 
Functionally, R3487/MEM3454, with a molecular weight of 
306.79, acted as a partial agonist in monkey recombinant 7 
nAChRs (EC50=0.4 nM) and displayed an antagonist action 
against native guinea pig 5-HT3 receptors. R3487/MEM3454 
lacked affinity at 42 nAChRs and had no activity at other 
nicotinic or other CNS receptor subtypes. Additionally, 
R3487/MEM3454 was demonstrated to be efficacious in 
several behavioral paradigms representing multiple cognitive 
domains (episodic, spatial, working, attentional and 
executive memory functions) in young and aged rodents as 
well as non-human primates.
** Interestingly, R3487/MEM-
3454 can increase both dopamine and ACh efflux in the rat 
medial prefrontal cortex and hippocampus when 
administered subcutaneously. These effects were completely 
blocked by MLA in both brain regions. 
  Currently RO5313534 (formerly R3487/MEM 3454) is 
being developed for treatment of AD and cognitive 
impairment in schizophrenia. Three different doses of 
RO5313534 (as R3487/MEM3454) were evaluated in a 
phase IIa trial in 80 patients with mild to moderate AD 
[146]. The 2 lower doses (5 and 15 mg/day) were associated 
with significant improvements compared with placebo on 
several efficacy measures (P0.05). Constipation was the 
only adverse event that was found to occur substantially 
more frequently in the R3487/MEM3454 groups compared 
with the placebo group (43% vs 5%, respectively); no 
serious adverse events were attributed to the study drug. A 
second phase II trial was initiated in April 2009 to assess the 
safety and efficacy of 4 different dosages of RO5313534 as 
an adjunctive therapy to donepezil 5 or 10 mg/day in patients 
with mild to moderate AD. 
                                                 
** Wallace, T.L.; Chiu, H.; Dao, D.A.; Lowe, D.A.; Porter, R.; Santarelli, L. 
R3487/MEM 3454, a novel nicotinic 7 receptor partial agonist, improves attention 
and working memory performance in cynomolgus macaques. Biochem. Pharmacol., 
2009, 78, 912. 
Servier 
  Researchers at Servier reported 2-[2-(4-bromophenyl)-2-
oxoethyl]-1-methyl pyridinium, S 24795 (Fig. 15), as a 
partial agonist for 7 nAChRs [147]. S 24795 was selected 
from a series of bromophenyl pyridinium derivatives. S 
24795 showed a moderate affinity to native rat 7 nAChR 
(IC50=4.6  μM) but did not show any affinity to 42 
nAChR, muscle-type nicotinic receptors or ganglionic-type 
nicotinic receptors. S 24795 is a partial agonist of 7 nAChR 
with an EC50 of 34 ± 11 μM and approximately 10% activity 
relative to ACh. S 24795 enhances long-term potentiation at 
CA3-CA1 synapses in the adult mouse hippocampus [148]. 
This effect was considered to be mediated by 7 nAChRs, 
since it was prevented by MLA (10 μM) and was absent in 
7-knockout mice. S 24795 improved contextual memory in 
aged mice [149] and aging-related deficits in declarative and 
working memory in mice [150]. Interestingly, in vitro 
exposure of S 24795 reduced the existing A427 nAChR 
complexes in AD frontal cortex synaptosomes [94]. 
Furthermore,  in vitro exposure of S 24795 normalized 7 
nAChR- and NMDA receptor-mediated Ca
2+ influx and 
improved NMDA receptor signaling in AD and A42-
exposed control brain synaptosomes. S 24795 facilitates 
A42 release from A427 nAChR and A42 complexes by 
interacting with the A15-20 region of A42, the pivotal A42-
binding domain to the 7 nAChR.  
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Fig. (15). Chemical structure of S 24795. 
 
EnVivo 
  Very recently, researchers at EnVivo Pharmaceuticals 
Inc. reported EVP-6124 as a novel 7 nAChR agonist.
†† The 
chemical structure of EVP-6124 was not disclosed. EVP-
6124 is a selective and potent 7 nAChR agonist (Ki = 4.3 
nM) that has antagonist activity at the 5-HT3 receptor (IC50 = 
299 nM), and limited or no activity on other receptors. EVP-
6124 has an excellent brain to plasma ratio and has shown 
marked efficacy and potency in a number of animal models 
of cognition. In rats with scopolamine-induced memory 
deficit, a single dose of EVP-6124 reverses the short-term 
memory impairment in an object-recognition task. In a 
model of natural forgetting of the novel objective-
recognition task, EVP-6124 was effective at preventing 
natural forgetting when given after the first trial. EVP-6124 
was also effective in this model when given after the first 
trial or when given only before the second trial. Furthermore, 
EVP-6124 also reversed scopolamine-induced deficits in a 
water maze repeated acquisition task model. These 
observations suggest that EVP-6124 may enhance 
                                                 
†† Koenig, G. EVP-6124, a novel 7 nAChR agonist for the treatment of cognitive 
impairments in Alzheimer’s disease & schizophrenia. Nicotinic acetylcholine receptors 
as therapeutic targets: emerging frontiers on basic research and clinical science; 
Chicago, IL, Oct. 14-Oct. 17, 2009. 50    The Open Medicinal Chemistry Journal, 2010, Volume 4  Toyohara and Hashimoto 
acquisition as well as consolidation and retrieval processes. 
Further preclinical investigation of EVP-6124 revealed a 
large safety margin relative to systemic exposure of EVP-
6124 based on the lack of an observable adverse effect level 
in dogs. In phase 1 clinical trials, the safety and tolerability 
of EVP-6124 has been demonstrated in healthy volunteers as 
well as in subjects with schizophrenia and AD. The efficacy 
of EVP-6124 is currently being investigated in AD as well as 
in cognitive impairment associated with schizophrenia. 
Tropisetron 
 Both  7 nAChRs and 5-HT3 receptors are members of 
the superfamily of ligand-gated ion channels [23, 28]. These 
two receptors share the greatest similarity within the family, 
displaying approximately 30% sequence homology [151]. 
Tropisetron and ondansetron (Fig. 16) are potent 5-HT3 
receptor antagonists that are widely used in the treatment of 
patients with chemotherapy-induced or postoperative nausea 
and vomiting [23]. It has been reported that tropisetron is a 
partial agonist of 7 nAChRs with a high affinity, whereas 
ondansetron has a weak affinity at 7 nAChRs [152, 153]. 
We found that tropisetron improves the deficient inhibitory 
processing of P20-N40 in DBA/2 mice, and that 
improvement by tropisetron could be antagonized by co-
administration of MLA [154]. Furthermore, we reported that 
PCP-induced cognitive deficits could be improved by 
subsequent subchronic administration of tropisetron, but not 
ondansetron, and that improvement by tropisetron could be 
antagonized by co-administration of MLA [155]. These 
findings suggest that tropisetron could improve abnormal 
auditory gating of P20-N40 and PCP-induced cognitive 
deficits in mice via 7 nAChRs. In addition, we reported that 
tropisetron (10 mg) could improve deficits of P50 
suppression in schizophrenic patients [156]. A randomized, 
placebo-controlled study of tropisetron on cognitive 
dysfunction in schizophrenic patients is currently underway 
at Chiba University. 
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Fig. (16). Chemical structure of tropisetron and ondansetron. 
 
CONCLUDING REMARKS 
  As described above, accumulating evidence suggests that 
7 nAChRs play an important role in the pathophysiology of 
neuropsychiatric diseases, including schizophrenia and AD. 
Hence, a number of pharmaceutical industries have 
developed selective and high affinity 7 nAChR agonists as 
therapeutic drugs for these neuropsychiatric diseases. Over 
the past decade, a variety of largely quinuclidine 
pharmacophore-based agonists of 7 nAChRs have 
emerged, including AR-R17779, PNU-282987, PHA-
543613, PHA-568487, W-56203, ABBF and JN403. In the 
past 10 years, several 7 nAChR agonists (DMXB-A, PHA-
543613, PHA-568487, R3487/MEM 3545 and tropisetron) 
have entered clinical trials for potential use in schizophrenia 
or AD. Today, lead optimization efforts and structure-
activity relationship studies have identified several different 
pharmacophore-based compounds, including biarylamine 
derivatives (TC-1698, TC-5619, PHA-709829, SSR180711, 
A-844606 and A-582941) and others. Some of these new 
compounds have entered preclinical validation studies as 
candidates for clinical trial. 
 In  vivo positron emission tomography (PET) imaging of 
7 nAChRs in the intact human brain provides a method for 
quantitative study of 7 nAChR-related pathophysiology in 
neuropsychiatric diseases [157]. Very recently, we 
developed the novel PET ligand, [
11C]CHIBA-1001 (Fig. 
17), for 7 nAChRs in the human brain [158, 159]. To the 
best of our knowledge, there are no other PET ligands for 7 
nAChRs available for human use. The in vivo determination 
of  7 nAChR receptor occupancy using PET and 
[
11C]CHIBA-1001 allows for demonstration of the target 
engagement and assessment of the titration for potential dose 
regimens in humans. In addition, a clinical PET study in 
patients with schizophrenia or AD using [
11C]CHIBA-1001 
is currently underway. 
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Fig. (17). Chemical structure of [
11C]CHIBA-1001. 
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ABBREVIATIONS 
ACh =  Acetylcholine 
AD =  Alzheimer’s  disease 
ADHD  =  Attention deficit hyperactivity disorder 
nAChR =  Nicotinic  acetylcholine  receptor 
5-HT3 =  5-hydroxytriptamine-3 
CNS =  Central  nervous  system 
CSF =  Cerebrospinal  fluid 
NMDA =  N-methyl-D-aspartate 
CHRNA7 =  7 nAChR subunit gene 
NB =  Nucleus  basalis 
A =  -Amyloid 
EC50  =  Half maximum (50%) effective concen- 
tration 
i.v. =  Intravenous 7 Nicotinic Receptor Agonists for Alzheimer’s Disease and Schizophrenia  The Open Medicinal Chemistry Journal, 2010, Volume 4    51 
i.p. =  Intraperitoneal 
p.o. =  Peroral 
s.c. =  Subcutaneous 
PPI =  Pre-pulse  inhibition 
Pgp =  P-glycoprotein 
hERG =  Human  ether-a-go-go 
JAK2  =  JANUS kinase 2 
PI3K =  Phosphoinositide  3-kinase 
Arc =  Activity-regulated  cytoskeleton-associated 
protein 
ERK1/2  =  Extracellular signal-regulated protein 1/2 
CREB  =  cAMP response element-binding protein 
GSK3  =  Glycogen synthase kinase 3 
DMXB-A =  3-(2,4)-dimethoxybenzilidine  anabaseine   
(GTS-21) 
DMAB =  3-(4)-dimethylaminobenzylidine  anabaseine 
DMAC =  3-(4)-dimethylaminocinnamylidine 
4-OH- =  3-(4-hydroxy-2-methoxybenzylidine)  ana- 
DMXB-A      baseine 
AR-R17779 = ()-spiro[1-azabicyclo[2.2.2]octane-3,5- 
oxazolidin-2-one] 
SIB1765F =  [±]-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)- 
pyridine fumarate 
AZD0328 =  (2R)-spiro-[1-azabicyclo[2.2.2]octane-3,2-  
(3H)-furo[2,3-b]pyridine D-tartrate 
W-56203 =  (R)-3-(3-methylbenzo[b]thiophen-5-yl)s- 
piro[1-azabicyclo[2.2.2]octane-3,5-oxazo-
lidin]-2-one 
AMPA =  -amino-3-hydroxy-5-methyl-4-isoxazole  
propionic acid 
MLA =  Methyllycaconitine 
Dizocilpine    =  (+)-5-methyl-10,11-dihydro-5H-dibenzo- 
(MK-801) [a,d]cyclohepten-5,10-imine maleate 
TC-1698 =  2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane 
TC-5619 =  N-{(2R,3R)-2-[(pyridine-3-yl)methyl]quin- 
uclidin-3-yl}benzofuran-2-carboxamide 
PNU-282987 =  N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chl- 
orobenzamide hydrochloride 
PHA-543613 =  N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[- 
2,3-c]pyridine-5-carboxamide 
PHA-568487 =  2,3-dihydro-N-[(R)-quinuclidine-3-yl]ben- 
zo[b][1,4]dioxine-6-carboxamide 
PHA-709829 =  N-[(3R,5R)-1-aza-bicyclo[3.2.1]octan-3-yl] 
furo[2,3-c]pyridine-5-carboxamid 
SSR180711 = 4-bromophenyl 1,4-diazabicyclo[3.2.2]no- 
nane-4-carboxylate hydrochloride 
PCP =  Phencyclidine 
CP-810,123 = 2-(5-methyloxazolo[4,5-b]pyridin-2-yl)-2,5 
-diaza-bicyclo[3.2.2]nonane 
SEN12333/  =  5-morphorino-4-yl-pentanoic acid (4-pyri- 
WAY-317538 din-3-yl-phenyl)-amide 
WYE-103914/= 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-[4-(pi-   
SEN34625   peridin-1-yl)butyl]urea 
ABBF =  N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2- 
(methoxy)phenyl]-1-benzofuran-2-
carboxamide 
Tilorone =  2,7-bis[2-(diethylamino)ethoxy]-9H-fluo- 
ren-9-one 
A-844606 =  2-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrr- 
ol-2-yl)-xanthen-9-one 
A-582941 =  2-methyl-5-(6-phenylpyridazin-3-yl)octa- 
hydropyrrolo[3,4-c]pyrrole 
JN403 =  (S)-(1-azabicyclo[2.2.2]oct-3-yl)-carbamic  
acid (S)-1-(2-fluoro-phenyl)-ethyl ester 
S 24795  =  2-[2-(4-bromophenyl)-2-oxoethyl]-1-met- 
hyl pyridinium 
Tropisetron = 8-methyl-8-aza-bicyclo[3.2.1]octan-3-yl   
indoline-3-carboxylate 
Ondansetron =  2,3,8a,9-tetrahydro-3-[(2-methyl-1H-imi- 
dazol-1-yl)methyl]-1H-carbazol-4(4bH)-
one 
[
11C]CHIBA-1001 = 4-[
11C]methylphenyl 1,4-diazabicyclo- 
[3.2.2]nonane-4-carboxylate 
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